Cargando…

Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2

BACKGROUND: Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disease characterized by development of schwannomas on the VIIIth (vestibular) cranial nerves. Bromodomain and extra-terminal domain (BET) proteins regulate gene transcription and their activity is required in a variety of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doherty, Joanne, Mandati, Vinay, González Rodriguez, Maria A, Troutman, Scott, Shepard, Alyssa, Harbaugh, David, Brody, Rachel, Miller, Douglas C, Kareta, Michael S, Kissil, Joseph L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278623/ https://www.ncbi.nlm.nih.gov/pubmed/35855490 http://dx.doi.org/10.1093/noajnl/vdac072

Ejemplares similares

Transcriptional regulation of miR-30a by YAP impacts PTPN13 and KLF9 levels and Schwann cell proliferation
por: Shepard, Alyssa, et al.
Publicado: (2021)

Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
por: Liu, Xin-Mo, et al.
Publicado: (2023)

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
por: Morgado-Pascual, Jose Luis, et al.
Publicado: (2019)

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
por: Moreno, Victor, et al.
Publicado: (2022)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo
por: Osum, Sara H, et al.
Publicado: (2021)

Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
por: Danielsen, Stine A., et al.
Publicado: (2015)

Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1
por: Tydings, Caitlin, et al.
Publicado: (2021)

Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma
por: Chen, Ye, et al.
Publicado: (2019)

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation
por: Stock, Carmel J. W., et al.
Publicado: (2019)

Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours
por: Mu, Jianfeng, et al.
Publicado: (2020)

Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma
por: Vichaikul, Sirapa, et al.
Publicado: (2022)

Regulation of localization and function of the transcriptional co-activator YAP by angiomotin
por: Moleirinho, Susana, et al.
Publicado: (2017)

Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
por: Keck, Kristin M., et al.
Publicado: (2017)

The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
por: Pan, Hanyu, et al.
Publicado: (2017)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation
por: Colardo, Mayra, et al.
Publicado: (2023)

Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy
por: Gargano, Deborah, et al.
Publicado: (2023)

The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer’s Disease
por: Matuszewska, Marta, et al.
Publicado: (2022)

Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma
por: Liu, Chen, et al.
Publicado: (2020)

Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration
por: Liu, Chen, et al.
Publicado: (2019)

An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival
por: Gittleman, Haley, et al.
Publicado: (2019)

Clinical validation of a spectroscopic liquid biopsy for earlier detection of brain cancer
por: Cameron, James M, et al.
Publicado: (2022)

Dual-center validation of using magnetic resonance imaging radiomics to predict stereotactic radiosurgery outcomes
por: DeVries, David A, et al.
Publicado: (2023)

Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2021)

Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
por: Chang Muñoz, Meilen, et al.
Publicado: (2020)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion
por: Hussein, Deema, et al.
Publicado: (2011)

Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
por: Pandey, Manjari, et al.
Publicado: (2022)

Primary CNS lymphoma commonly expresses immune response biomarkers
por: Ou, Alexander, et al.
Publicado: (2020)

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
por: Mitchell, Leah A., et al.
Publicado: (2017)

Bromodomain and extraterminal (BET) protein inhibitor, apabetalone, reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro
por: Gilham, D, et al.
Publicado: (2021)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin
por: Zats, Liat Peretz, et al.
Publicado: (2022)

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity
por: Hiraoka, Kei, et al.
Publicado: (2017)

The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment
por: Mrugala, Maciej M, et al.
Publicado: (2021)

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector
por: Ostertag, Derek, et al.
Publicado: (2012)

TGF-β promotes microtube formation in glioblastoma through thrombospondin 1
por: Joseph, Justin V, et al.
Publicado: (2021)

Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes
por: Frenster, Joshua D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v6099uc5ttqad05bh9rvsmgve4